有毛用_老虎社区_美港股上老虎

游侠46
2020-12-16

有毛用

Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示，Kite 的 Tecartus 获得有条件营销授权，用于在欧洲治疗复发性或难治性套细胞淋巴瘤</blockquote>

Gilead Sciences Inc :Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The

Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示，Kite 的 Tecartus 获得有条件营销授权，用于在欧洲治疗复发性或难治性套细胞淋巴瘤</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

dd0101
·2020-12-16
然并卵
回复
点赞
举报

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":394730525,"tweetId":"394730525","gmtCreate":1608107182167,"gmtModify":1703851175832,"author":{"id":3550397726856888,"idStr":"3550397726856888","authorId":3550397726856888,"authorIdStr":"3550397726856888","name":"游侠46","avatar":"https://static.tigerbbs.com/fdf884593a23efe97b6389afbcc683b0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>有毛用</p></body></html>","htmlText":"<html><head></head><body><p>有毛用</p></body></html>","text":"有毛用","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/394730525","repostId":2091538377,"repostType":2,"repost":{"id":"2091538377","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1608106179,"share":"https://www.laohu8.com/m/news/2091538377?lang=zh_CN&edition=full","pubTime":"2020-12-16 16:09","market":"hk","language":"en","title":"Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示，Kite 的 Tecartus 获得有条件营销授权，用于在欧洲治疗复发性或难治性套细胞淋巴瘤</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2091538377","media":"T-Reuters","summary":"Gilead Sciences Inc :Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The ","content":"<p><html><body>Gilead Sciences Inc <gild.o>:Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe.93 Percent Of Patients In Zuma-2 Pivotal Trial Responded To Single Infusion Of Tecartus.Gilead Sciences</gild.o></p><p><blockquote><html><body>吉利德科学公司<gild.o>:风筝的Tecartus™（Kte-X19）在欧洲获得治疗复发或难治性套细胞淋巴瘤的有条件营销授权。Zuma-2关键试验中93%的患者对单次输注Tecartuss有反应。吉利德科学</gild.o></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示，Kite 的 Tecartus 获得有条件营销授权，用于在欧洲治疗复发性或难治性套细胞淋巴瘤</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe<blockquote>吉利德科学表示，Kite 的 Tecartus 获得有条件营销授权，用于在欧洲治疗复发性或难治性套细胞淋巴瘤</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2020-12-16 16:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Gilead Sciences Inc <gild.o>:Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe.93 Percent Of Patients In Zuma-2 Pivotal Trial Responded To Single Infusion Of Tecartus.Gilead Sciences</gild.o></p><p><blockquote><html><body>吉利德科学公司<gild.o>:风筝的Tecartus™（Kte-X19）在欧洲获得治疗复发或难治性套细胞淋巴瘤的有条件营销授权。Zuma-2关键试验中93%的患者对单次输注Tecartuss有反应。吉利德科学</gild.o></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2091538377","content_text":"Gilead Sciences Inc :Kite’S Tecartus™ (Kte-X19) Granted Conditional Marketing Authorization For The Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe.93 Percent Of Patients In Zuma-2 Pivotal Trial Responded To Single Infusion Of Tecartus.Gilead Sciences","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":5301,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":3194008,"commentId":"3194008","gmtCreate":1608109312547,"gmtModify":1608113966746,"authorId":3482380532740739,"author":{"id":3482380532740739,"idStr":"3482380532740739","authorId":3482380532740739,"name":"dd0101","avatar":"https://static.tigerbbs.com/4a38ca54c112ac9c6274b68633d24a30","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":394730525,"objectIdStr":"394730525","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"然并卵","text":"然并卵","html":"然并卵","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}

评论（1）

热议股票